TriangleNCT00142168 · OUTCOME
Minor Response Rate
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- participants
- Interval / dispersion
- Not reported
- Time frame
- 34.3 months
What was measured
A minor response is defined as having achieved \>25% but less than 50% reduction in serum IgM levels.
Analysis population: Evaluable patients. 4 participants were withdrawn for adverse events and were unevaluable.
Groups in this outcome
Lenalidomide and Rituximab
Intended therapy consisted of 48 weeks of lenalidomide (25 mg/d for 3 weeks and then 1 week off) along with rituximab (375 mg/m(2)/wk) dosed on weeks 2 to 5 and 13 to 16.
| Group | Source count |
|---|---|
| Lenalidomide and Rituximab | 12 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Lenalidomide and Rituximab | 4 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 4
- denoms
- counts
- group Id
- OG000
- value
- 12
- units
- Participants
- description
- A minor response is defined as having achieved \>25% but less than 50% reduction in serum IgM levels.
- groups
- description
- Intended therapy consisted of 48 weeks of lenalidomide (25 mg/d for 3 weeks and then 1 week off) along with rituximab (375 mg/m(2)/wk) dosed on weeks 2 to 5 and 13 to 16.
- id
- OG000
- title
- Lenalidomide and Rituximab
- param Type
- NUMBER
- population Description
- Evaluable patients. 4 participants were withdrawn for adverse events and were unevaluable.
- reporting Status
- POSTED
- time Frame
- 34.3 months
- title
- Minor Response Rate
- type
- SECONDARY
- unit Of Measure
- participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice